Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595820 | 0.84 | TDP1 (0.41) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL31595924 | 0.84 | TDP1 (0.41) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL11900275 | 0.79 | TDP1 (0.43) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL13574810 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL2520194 | 0.76 | TDP1 (0.41) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL16935016 | 0.76 | ALDH1A1 (0.37) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL12714343 | 0.73 | TDP1 (0.39) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL1614010 | 0.73 | TDP1 (0.39) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL2517149 | 0.72 | TDP1 (0.38) | ALDH1A1KCNJ1TDP1MAPTKDM4E | |
| SCHEMBL10227902 | 0.71 | ALDH1A1 (0.36) | ALDH1A1KCNJ1TDP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098047-A1 | Anti-Giardial Compounds | COMMW SCIENT IND RES ORG (AU) | 2026-04-09 | — | — | US | disclosed |
| EP-4608823-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024088922-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-02 | — | — | WO | disclosed |
| CN-117800944-A | Pyridine amide derivative, pharmaceutical composition containing same and medical application of pharmaceutical composition | 苏州阿尔脉生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117800894-A | Saturated cyclic derivative, pharmaceutical composition containing same and medical application of saturated cyclic derivative | 苏州阿尔脉生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4334306-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| EP-3372589-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-3102573-B1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| WO-2015118019-A9 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015118019-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2015-08-13 | — | — | WO | disclosed |
| CN-1081675-A | By the new pyrethroid of thiazolic alcohol derivative, its preparation method and as the purposes of agricultural chemicals | ROUSSEL UCLAF (FR) | 1994-02-09 | — | — | CN | disclosed |
| EP-0556123-A1 | Pyrethrinoid esters of thiazolylalcohols, process for their preparation and their use as pesticides | ROUSSEL UCLAF (FR) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | P2RX7, P2RX1, P2RX2 | ALDH1A1 1516/4885KCNJ1 301/4885TDP1 1459/4885 |
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | TRPV1, SCN8A, SCN2A | ALDH1A1 2844/4885KCNJ1 32/4885TDP1 4714/4885 |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | ALDH1A1 1516/4885KCNJ1 301/4885TDP1 1459/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | ALDH1A1 1488/4885KCNJ1 2392/4885TDP1 3116/4885 |
| US-20260098047-A1 | Anti-Giardial Compounds | GNAO1, GPR6, MGAT3 | ALDH1A1 2383/4885KCNJ1 1908/4885TDP1 4287/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ALDH1A1 411/4885KCNJ1 1640/4885TDP1 2538/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | ALDH1A1 865/4885KCNJ1 1214/4885TDP1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.